Skip to main content

ANALISIS MULTI-EPIGENOMICO DE LA BIOPSIA LIQUIDA PARA SUPERAR LA RESISTENCIA A LA TERAPIA EN EL CÁNCER COLORRECTAL METASTÁSICO

PI23/00721

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Salud
Call year 2023
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PUBLICA GALEGA INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA
Execution centre INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA (IDIS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Circulating tumor DNA in patients with cancer, insights from clinical laboratory

  • Illana Cámara, Francisco José|||0009-0001-9717-5688
  • Muñoz-Bravo, José Luis|||0000-0001-6253-8330
  • González-Fernández, Carolina
  • Trapé, Jaume
  • Diaz-Lagares, Angel|||0000-0002-9114-9227
  • Fernández-Galán, Esther
  • Valiña Amado, Laura
  • Garcia-Martín, Carme
  • Miró-Cañís, Sílvia
  • Martínez-Peinado, Antonio
  • Filella, Xavier
  • González, Alvaro
  • Barco Sánchez, Antonio
Blood-based circulating tumor DNA (ctDNA) analysis has emerged as a highly relevant non-invasive method for molecular profiling of solid tumors, offering valuable information about the genetic landscape of cancer. Somatic mutation analysis of ctDNA is now used clinically to guide targeted therapies for advanced cancers. Recent advancements have also revealed its potential in early detection, prognosis, minimal residual disease assessment, and prediction/monitoring of therapeutic response. In recent years, significant progress has been made with the development of various PCR and NGS-based methods designed for assessing gene variants in ctDNA of patients with cancer. However, despite the transformative possibilities that ctDNA analysis presents, challenges persist. Standardization of preanalytical and analytical protocols, assay sensitivity, and the interpretation of results remain critical hurdles that need to be addressed for the widespread clinical implementation of ctDNA testing. In addition to somatic mutations, emerging studies on DNA methylation (epigenomics) and fragment size patterns (fragmentomics) in several types of biological fluids are yielding promising results as non-invasive biomarkers for effective cancer management. This review addresses the clinical applications of somatic gene variants in ctDNA, emphasizes their potential as cancer biomarkers, and highlights essential factors for successful implementation in clinical laboratories and cancer management.